Potiga Articles
US FDA moves approval goalposts for GSK/Valeant’s ezogabine and Eisai’s eribulin; Abbott/Eisai’s Humira filed for additional indication in Japan
1 September 2010
Showing 1-3 of 3 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
